Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $2.02 for the day, down -4.27% from the previous closing price of $2.11. In other words, the price has decreased by -$4.27 from its previous closing price. On the day, 1.52 million shares were traded. CCCC stock price reached its highest trading level at $2.1 during the session, while it also had its lowest trading level at $1.99.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $8.
On September 15, 2025, Stephens Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $6.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $8.Guggenheim initiated its Buy rating on September 04, 2025, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share. On Nov 18 ’24, another insider, Salter Malcolm, who serves as the Director of the company, bought 13,000 shares for $4.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 150170416 and an Enterprise Value of -7865953. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.20 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at -0.23 whereas that against EBITDA is 0.065.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.96, which has changed by -0.7114286 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $7.14, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -20.17%, while the 200-Day Moving Average is calculated to be -12.17%.
Shares Statistics:
CCCC traded an average of 1.82M shares per day over the past three months and 2854560 shares per day over the past ten days. A total of 71.01M shares are outstanding, with a floating share count of 59.98M. Insiders hold about 15.73% of the company’s shares, while institutions hold 65.80% stake in the company. Shares short for CCCC as of 1759190400 were 3521151 with a Short Ratio of 1.94, compared to 1756425600 on 3781945. Therefore, it implies a Short% of Shares Outstanding of 3521151 and a Short% of Float of 5.3400002.
